I did allogenic NK/DC Cell therapy (peripheral blood) in Japan earlier in the year, with a CEA peptide vaccine (not personalised as I couldn’t readily import tumour tissue) and a lower dose of cetuximab. Other than a pretty severe rash I didn’t notice any major immediate effects, except I was exhausted by the end of the treatment (could be the Tokyo Tiredness…). The positive change in my cell counts afterward were significant, of course. Very difficult to say if I had any clinical benefit as it was n=1 without a control, however I got Influenza A shortly after and sailed through with almost zero symptoms (they kept me in hospital as I was a chemo patient but couldn’t believe how fine I was). I had modest disease stability afterward, but no obvious regression.
They generally prefer you to combine it with something like radiotherapy (abscopal effect) or chemotherapy, as the monotherapy results aren’t super strong.
Dr Terunuma is often considered one of the emergent experts in the field, and he treats in several clinics in Tokyo (and one regionally, I think). Eg below (N2 Clinic). Lots of papers you can read too.
https://n2clinic-ginza.com/en/
https://www.researchgate.net/profile/Hiroshi-Terunuma
In Japan this is often marketed alongside other wellness and “longevity” treatments like stem cell therapies, however in my experience the vast majority of their client base is cancer patients.
One strong positive is that they have invested in their own lab capacity for cell analysis and expansion/storage. Many providers outsource their lab work (who in turn may again outsource…), which has led to some cases of quality issues in the past - even in Germany.
Like most things in life, it isn’t cheap.